Meinolf Karthaus

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

Johan Maertens, Issam Raad, Kieren A. Marr et al. · The Lancet · 2015 · 938 citations

Antifungal Agent, Isavuconazole Versus Voriconazole, Antifungal Agents +7

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type <i>KRAS</i> Exon 2 Metastatic Colorectal Cancer

Lee S. Schwartzberg, Fernando Rivera, Meinolf Karthaus et al. · Journal of Clinical Oncology · 2014 · 623 citations

Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

Johan Maertens, Galia Rahav, Dong‐Gun Lee et al. · The Lancet · 2021 · 257 citations · Full text

Invasive Aspergillosis, Posaconazole Versus Voriconazole, Antifungal Agent +5

Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program

Armando Santoro, Mary O’Brien, Rolf A. Stahel et al. · Journal of Thoracic Oncology · 2008 · 247 citations

Chemonaïve Patients, Malignant Pleural Mesothelioma, Medicine +6

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial

Meinolf Karthaus, Albrecht Kretzschmar, H. Kröning et al. · Annals of Oncology · 2005 · 219 citations · Full text

Venous Disease, Oncology, Venous Thrombosis +10